A Network Meta-Analysis of Two Doses of Recombinant Human Thrombopoietin for Treating Sepsis-Related Thrombocytopenia

<div>Evidence network of 28-day mortality. NAT, no additional treatment; IVIG, intravenous immunoglobulin; rhTPO 300, 300 U/kg/d recombinant human thrombopoietin; rhTPO 15000, 15000 U/d recombinant human thrombopoietin.</div>

International Journal of Clinical Practice

fig2

Figure 2

Figure 2: A Network Meta-Analysis of Two Doses of Recombinant Human Thrombopoietin for Treating Sepsis-Related Thrombocytopenia 